Serum amyloid A as a potent therapeutic marker in a refractory patient with polymyalgia rheumatica

Internal Medicine

Volumn 44, Issue 9, 2005, Pages 1009-1012

  Shimojima, Yasuhiro ^a   Matsuda, Masayuki ^a   Gono, Takahisa ^a   Ishii, Wataru ^a   Ikeda, Shu Ichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

C reactive protein; Erythrocyte sedimentation rate; Flow cytometry; Polymyalgia rheumatica; Remitting seronegative symmetrical synovitis with pitting edema; Serum amyloid A

Indexed keywords

AMYLOID A PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CORTICOSTEROID; PREDNISOLONE;

AGED; ARTICLE; CASE REPORT; CLINICAL PROTOCOL; DISEASE ACTIVITY; DRUG DOSE REGIMEN; EDEMA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLOW CYTOMETRY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MUSCLE STIFFNESS; MYALGIA; PHYSICAL EXAMINATION; PROTEIN BLOOD LEVEL; RELAPSE; RHEUMATIC POLYMYALGIA; SYMPTOM; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; POLYMYALGIA RHEUMATICA; PREDNISOLONE; SERUM AMYLOID A PROTEIN;

EID: 27844548029     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.44.1009     Document Type: Article

References (20)

1. Douglas WA, Martin BA, Morris JH. Polymyalgia rheumatica: an arthroscopic study of the shoulder joint. Ann Rheum Dis 42: 311-316, 1983.
2. Chou CT, Schumacher HR Jr. Clinical and pathologic studies of synovitis in polymyalgia rheumatica. Arthritis Rheum 27: 1107-1117, 1984.
3. + T cells in polymyalgia rheumatica and giant cell arteritis: a review. Semin Arthritis Rheum 30: 257-271, 2001.
4. Weyand CM, Fulbright JW, Evans JM, Hunder GG, Goronzy JJ. Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 159: 577-584, 1999.
5. Hachulla E, Saile R, Parra HJ, et al. Serum amyloid A concentrations in giant-cell arteritis and polymyalgia rheumatica: a useful test in the management of the disease. Clin Exp Rheumatol 9: 157-163, 1991.
6. Yamane T, Yamauchi H, Abe N, et al. Serum amyloid A as a useful index of disease activity in polymyalgia rheumatica. Ryumachi 43: 544-548, 2003 (in Japanese).
7. Cimmino MA, Salvarani C. Classification and assessment of rheumatic diseases: polymyalgia rheumatica and giant cell arteritis. Baillieres Clin Rheumatol 9: 515-527, 1995.
8. McCarty DJ, O'Duffy JD, Pearson L, Hunter JB. Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome. JAMA 254: 2763-2767, 1985.
9. Oide T, Ohara S, Oguchi K, et al. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome in Nagano, Japan: clinical, radiological, and cytokine studies of 13 patients. Clin Exp Rheumatol 22: 91-98, 2004.
10. Cimmino MA, Silvestri E, Garlaschi G. Remitting seronegative, symmetrical synovitis with pitting oedema (RS3PE) as recurrence of aborted PMR. Ann Rheum Dis 60: 303, 2001.
11. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324, 1988.
12. Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med 37: 381-388, 1999.
13. Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun 314: 363-369, 2004.
14. Thorn CF, Lu ZY, Whitehead AS. Regulation of the human acute phase serum amyloid A genes by tumor necrosis factor-alpha, interleukin-6 and glucocorticoids in hepatic and epithelial cell lines. Scand J Immunol 59: 152-158, 2004.
15. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340: 448-454, 1999.
16. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 121: 484-491, 1994.
17. Uddhammar A, Sundqvist KG, Ellis B, Rantapaa-Dahlqvist S. Cytokines and adhesion molecules in patients with polymyalgia rheumatica. Br J Rheumatol 37: 766-769, 1998.
18. Macchioni P, Boiardi L, Salvarani C, et al. Lymphocyte subpopulations analysis in peripheral blood in polymyalgia rheumatica/ giant cell arteritis. Br J Rheumatol 32: 666-670, 1993.
19. Lopez-Hoyos M, Bartolome-Pacheco MJ, Blanco R, Rodriguez-Valverde V, Martinez-Taboada VM. Selective T cell receptor decrease in peripheral blood T lymphocytes of patients with polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis 63: 54-60, 2004.
20. Salvarani C, Boiardi L, Macchioni P, et al. Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis 54: 640-644, 1995.